Page 76 - Read Online

Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11 Page 165

172. Lee HY, Kim DJ, Lee HJ, Choi JE, Kim YK. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR)
with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol
Biol Psychiatry 2009;33:276-80. DOI PubMed
173. Vázquez-Bourgon J, Arranz MJ, Mata I, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in
first episode of psychosis. Psychiatry Res 2010;175:189-94. DOI
174. Xu Q, Wu X, Li M, et al. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and
chlorpromazine in the Chinese Han population. Pharmacogenomics J 2016;16:357-65. DOI
175. Ruderfer DM, Charney AW, Readhead B, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic
medicine approach. Lancet Psychiatry 2016;3:350-7. DOI PubMed PMC
176. Gardner KR, Brennan FX, Scott R, Lombard J. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J
2014;2014:730956. DOI PubMed PMC
177. Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues
Clin Neurosci 2016;18:323-37. DOI PubMed PMC
178. Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits
and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 2018;86:36-44. DOI PubMed